Does adding concomitant immunosuppressive therapy to belimumab provide additional benefits in SLE? Results from the BEL-Spain Registry.
Frade-Sosa B, Gómez-Puerta JA, Altabás-González I, Pego-Reigosa JM, Casafont-Solé I, Salman-Monte TC, Hernández-Martín A, Román-Ivorra JA, Piqueras-García M, Garrote-Corral S, Tomero E, de la Mata-Pinilla E, Calvo-Alén J, Martínez-Barrio J, Vidal-Montal P, Cortés-Hernández J, Ramos-Giráldez C, Novoa FJ, Torrente-Segarra V, Fragio-Gil J, Riancho-Zarrabeitia L, Rúa-Figueroa I; BELIMUMAB Multicenter Spanish Register Group (BEL-Spain).
Frade-Sosa B, et al. Among authors: novoa fj.
Rheumatology (Oxford). 2026 Jun 3;65(6):keag076. doi: 10.1093/rheumatology/keag076.
Rheumatology (Oxford). 2026.
PMID: 41649458